Zacks Investment Research upgraded shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) from a sell rating to a hold rating in a research note published on Thursday morning.
According to Zacks, “Reckitt Benckiser Group Plc engages in manufacturing and distributing household, toiletry, pharmaceutical and food products. The company offers antiseptic liquids, depilatory products, medicated sore throat products, condoms, cold/flu products, acne treatment products, analgesics and upper gastro-intestinal products, foot care and comfort footwear products, denture care and dry skin care products, fabric care products, surface care products and polishes/waxes. Reckitt Benckiser Group is based in Slough, the United Kingdom. “
Separately, BNP Paribas raised shares of RECKITT BENCKIS/S from a neutral rating to an outperform rating in a research report on Tuesday, November 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $21.00.
Shares of RECKITT BENCKIS/S stock traded down $0.07 during trading on Thursday, hitting $15.91. 101,048 shares of the stock were exchanged, compared to its average volume of 503,562. The stock has a market cap of $58.76 billion, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 4.32 and a beta of 1.03. RECKITT BENCKIS/S has a 12-month low of $15.14 and a 12-month high of $21.79. The company has a current ratio of 0.68, a quick ratio of 0.50 and a debt-to-equity ratio of 0.75.
RECKITT BENCKIS/S Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: SEC Filing
Get a free copy of the Zacks research report on RECKITT BENCKIS/S (RBGLY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.